COMP <GO>
CRDF vs OKYO // 10Y YIELD & FRED MACRO BETA
Cardiff Oncology Inc. (NASDAQ) VS. OKYO Pharma Limited (NASDAQ) • 15-METRIC TALLY: CRDF 0
— OKYO 2
■ METRIC PARITY
LAST: $0.89 (-2.46%) • MKT CAP: $70.9M
macro-sensitivity
—
LAST: $1.47 (-2.00%) • MKT CAP: $78.7M
macro-sensitivity
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CRDF VS. OKYO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CRDF | OKYO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | — | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | -60.00% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | -7.70% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | -13.20% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 1/9 | — | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 38.9 | 52.8 | -13.96 | OKYO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta ACTIVE | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $70.9M | $78.7M | -$7.8M | OKYO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CRDF REV | OKYO REV | CRDF GROSS % | OKYO GROSS % | CRDF FCF | OKYO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $593.0K | — | — | — | -$38.0M | — |
| FY 2024 | $683.0K | — | — | — | -$37.8M | — |
| FY 2023 | $488.0K | — | — | — | -$30.9M | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CRDF // BETA —
OKYO // BETA —